Replay Holdings LLC has announced a research collaboration between Jura Bio Inc. and Syena, a cell therapy product company launched by Replay and the University of Texas MD Anderson Cancer Center earlier this year, to develop T-cell receptor (TCR)-based therapies.

Evaxion Biotech A/S has established a collaboration with Afrigen Biologics Pty Ltd. aimed at developing a prophylactic mRNA vaccine against gonorrhea.

Orionis Biosciences BV has established a multiyear collaboration with Genentech Inc., a member of the Roche Group, to discover novel small-molecule molecular glues for targets in major disease areas, including oncology and neurodegeneration.

Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

Benevolentai Ltd. has signed a strategic collaboration with Merck KGaA to identify novel drug candidates, initially for three targets in oncology, neurology and immunology.

Evaxion Biotech A/S has announced the initiation of a novel pipeline program, EVX-B3, an artificial intelligence (AI)-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be the subject of a co-funded collaboration between Evaxion and an undisclosed partner.

Biontech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have established a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT-166 for the prevention of mpox (formerly monkeypox).

Dewpoint Therapeutics Inc. and Chemify Ltd. have partnered to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

Proteros Biostructures GmbH has established a new collaboration with Orion Corp. The two companies are engaging in a joint multitarget collaboration for early-stage drug discovery projects in oncology and pain using Proteros’ discovery platform, and now have decided to combine their expertise to assemble a chemically diverse small-molecule library collection. The nonexclusive agreement enables Proteros to exclusively offer access to this high throughput screening (HTS) library to all its clients.